Study to Investigate the Safety, Tolerability, Mechanism of Action and Exploratory Clinical Efficacy of Repeat Dose HF1020 in Patients with Moderate to Severe Psoriasis

Trial Profile

Study to Investigate the Safety, Tolerability, Mechanism of Action and Exploratory Clinical Efficacy of Repeat Dose HF1020 in Patients with Moderate to Severe Psoriasis

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs HF 1020 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Nov 2014 Status changed from suspended to completed as reported by United Kingdom Clinical Research Network record.
    • 05 Oct 2013 Status changed from recruiting to suspended as reported by United Kingdom Clinical Research Network.
    • 08 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top